Synergy Pharma (SGYP) Tops Q1 EPS by 1c, Sales Miss; Guides Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update
May 10, 2018 4:15 PM EDTTRULANCE only CIC/IBS-C Rx brand to grow in total and new Rx volume quarter-over-quarter, per IQVIA Synergy lowers 2018 adjusted operating expense (non-GAAP) guidance Initiated strategic partnership with the National Cancer Institute (NCI) to collaborate on study to evaluate dolcanatides potential to prevent colorectal cancer Conducting ongoing review of strategic business development options focused on maximizing shareholder value
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the... More
